Business
Lynparza approved in EU for prostate cancer
Lynparza approved in EU for prostate cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n 21 December 2022 07:05 GMT\n \n \n \n \n \n \n Lynparza\n \n \n in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer\n \n \n \n \n \n \n \n \n \n First approved PARP inhibitor to demonstrate clinically meaningful benefits in combination with a new hormonal agent\n \n \n \n \n \n \n \n \n \n Lynparza in combination with abiraterone extended median radiographic progression-free survival benefit beyond two years in this setting\n \n \n \n \n \n \n \n \n AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men for whom chemotherapy is not clinically indicated.\n \n \n \n \n \n This approval by the European Commission was based on results from the\n \n \n PROpel Phase III trial\n \n \n and\n follows the positive\n \n \n recommendation\n \n \n in the EU by the Committee for Medicinal Products for Human Use in November 2022.\n \n \n \n \n \n In the trial, Lynparzain combination with abiraterone and prednisone or prednisolone, reduced the risk of disease progression or death by 34% versus abiraterone and prednisone or prednisolone (based on a hazard ratio [HR] of 0.66; 95% confidence interval [CI] 0.54-0.81; p<0.0001). Median radiographic progression-free survival (rPFS) was 24.8 months for Lynparza plus abiraterone versus 16.6 months for abiraterone alone. Furthermore, a planned rPFS analysis by blinded independent central review (BICR) showed Lynparza plus abiraterone had a median rPFS of 27.6 months compared to 16.4 months with abiraterone alone, extending median rPFS by almost one year.\n \n \n \n \n \n Updated results from a second planned analysis presented at ESMO 2022 showed a favourable trend towards improved overall survival with Lynparza plus abiraterone versus abiraterone alone (based on HR of 0.83; 95% CI 0.66-1.03; p=0.11), however, the difference did not reach statistical significance at the time of this data cut-off (analysis at 40% data maturity).\n \n \n \n \n \n Prostate cancer is the most common cancer in men in Europe, with an estimated 473,000 patients diagnosed and 108,000 deaths in 2020.1,2 Over...